Natera's Signatera Wins Japan Approval for Colorectal Cancer, Launch Expected by Year-End
NTRA sits 78% above its 52-week low of $131.811.
Summary
Natera's Signatera test received regulatory approval in Japan for colorectal cancer, with commercial launch expected by year-end 2026. This opens a significant new international market for a key oncology product, expanding Natera's addressable market and potential revenue. This follows recent positive regulatory news, including FDA approval for Signatera CDx in bladder cancer in May, and builds on strong Q1 2026 revenue growth.
At the time of this announcement, NTRA was trading at $235.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $33.6B. The 52-week trading range was $131.81 to $256.36. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.